Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a preclinical materials science study reporting rational design and in vitro/in vivo characterization of a nanoagent; it raises mechanistic questions about nanoparticle performance but does not test efficacy against a comparator in any clinical or disease model.
This systematic review of preclinical animal models raises mechanistic questions about PDT's potential to trigger systemic immunity but does not provide clinical evidence sufficient to guide practice or confirm efficacy in humans.
Phase II trial with modest sample size showing acceptable safety profile and 40% response rate for dysphagia in advanced esophageal cancer, but requires larger confirmatory studies before clinical adoption.
Sound preclinical study with in vitro biofilm efficacy and in vivo proof-of-concept in a rat caries model, but limited to animal data and lacks human clinical validation.
This is a proof-of-concept study of a novel photosensitizer design in a single tumor model with intratumoral dosing and short-term follow-up, demonstrating feasibility but lacking comparator arms, efficacy benchmarking, or systemic biodistribution data needed to establish clinical potential.
Early-stage in vitro chemical and cellular work demonstrating a novel synthesis and mechanism, lacking animal efficacy data, clinical translation, or comparative trials needed to support therapeutic claims.
This is a preclinical proof-of-concept study in cell culture and tumor-bearing mice demonstrating a novel self-assembled nanoparticle probe; no clinical efficacy data, no human trials, and no quantified survival or tumour response metrics are reported.